Sarepta's Additional Data Doesn't Sway FDA On Eteplirsen
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency reviewers raise more concerns about efficacy of proposed Duchenne muscular dystrophy treatment despite new information.